Skip to main content
ALPS logo

Alps Group Inc (ALPS) Stock Price & Analysis

Alps Group Inc (ALPS) — MoonshotScore 33/100 (Weak band), calculated Nov 18, 2026. Price $1.19 (0.00%), as of the Nov 19, 2026 trading session; market cap $37.7M.

Educational signal · not a buy or sell recommendation · How to read this

$1.19 $0.00 (0.00%) Market Cap $37.7M

Alps Group Inc · ALPS · NASDAQ

Alps Group Inc is an integrated biotechnology platform based in Kuala Lumpur, focusing on advanced therapies. The company provides research and development, medical services, and wellness solutions.

Price as of Nov 19, 2026

Key Statistics

33 of 100

MoonshotScore v2 · Alps Group (ALPS)

Weak
Business Quality Average (50)
Financial Safety Okay (56)
Valuation Bubble (9)
Growth Durability Flat (43)
Momentum Slipping (27)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

An expensive valuation, though quality and growth are only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Flat; Momentum: Slipping.

Earnings yield is the main valuation drag relative to sector peers.

  • Altman Z -1.76 · Piotroski F 3

Holding back: a rich price, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ALPS (52 recorded, newest six shown)
RecordedScoreBand
50Fair
51Fair
51Fair
51Fair
33Weak
33Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.19
Change on the day0.00%
Market capitalisation$37.7M—
Shares traded on the day71.7K

Price & events

Other perspectives

Council score for Alps Group (ALPS): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Neutral
Valuation Negative
Growth Durability Neutral
Momentum Weak

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
ROE Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Alps Group (ALPS), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Alps Group Inc (ALPS) is listed on NASDAQ. The market values it at $37.7M.

3 · Financial strengths and risks

What are the financial strengths and risks for Alps Group (ALPS)?

Short answer · as of

What is holding it back is a rich price, weak price trend. The distress and quality screens read Altman Z -1.76 · Piotroski F 3.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -1.76 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Alps Group compare with its peers?

Short answer

Alps Group's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Alps Group (ALPS) — this page$1.19$37.7M33

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ALPS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ALPS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Alps Group (ALPS)?

Read these with our analysis →

Common Questions About ALPS

These answers are editorial: 1 of these 9 answers is drawn from the ALPS research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ALPS?

ALPS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Alps Group Inc is an integrated biotechnology platform based in Kuala Lumpur, focusing on advanced therapies.

Is ALPS a good stock to buy?

Stock Expert AI does not rate ALPS buy, sell or hold. Alps Group Inc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ALPS stock price today?

The last price recorded for Alps Group Inc (ALPS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for ALPS?

Alps Group Inc faces several key risks, including its negative profit margin, which may limit its ability to fund research and development activities.

What are the key factors to evaluate for ALPS?

Alps Group Inc (ALPS) holds a MoonshotScore in the low range. These markets often have unmet healthcare needs and a growing demand for advanced therapies and wellness solutions. Not financial advice.

How frequently does ALPS data refresh on this page?

ALPS's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ALPS's recent stock price performance?

Alps Group Inc (ALPS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated biotechnology platform. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ALPS overvalued or undervalued right now?

Alps Group Inc (ALPS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of ALPS?

Fractional-share availability for Alps Group Inc (ALPS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 8 figures on this page — 4 from Financial Modeling Prep (FMP), 2 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.